Body photo
Vantia logo

Developing novel small molecule drugs targeting large areas of unmet medical need

Skip to main content


Novo Holdings A/S

Established in 2000, Novo Holdings A/S is the holding company of the Novo Group and is wholly owned by the Novo Nordisk Foundation. Novo Holdings A/S is the majority shareholder in the publicly listed companies, Novo Nordisk A/S and Novozymes A/S. Novo Holdings A/S provides seed, venture and growth capital to companies within life science and biotechnology. It also handles a broad portfolio of financial assets. In total, Novo A/S has more than USD 20 billion under management. Through Novo Ventures, Novo Holdings A/S invests venture capital in biotechnology and life science companies. Click here for more information:

MVM Life Science Partners

MVM was founded in 1997 and manages three funds totalling $500 million. MVM has invested in biopharmaceuticals, diagnostics, drug delivery, gene therapy, healthcare IT, healthcare services, medical devices, OTC medicines, research tools and vaccines. Current portfolio companies are based across Europe, Israel and in the US. The MVM team has broad experience across the life science and venture capital markets and maintains offices in London and Boston. Click here for more information:

SV Health Investors

SV Health Investors is a leading international life sciences venture capital firm. SVLS affiliated funds have been investing in life sciences companies since the early 1980s and the firm closed its first dedicated life sciences fund in 1994. The SV Health Investors team manages five private venture capital funds with approximately $2.0 billion of capital under management. The firm employs a diversified strategy within life sciences in order to selectively capitalize on an expanding opportunity in biotech, medical devices and healthcare services. SVLS has offices in Boston, London and San Francisco. Click here for more information: